LTR Pharma Logo

LTR Pharma

LTR Pharma is a Clinical Stage Biopharmaceutical Company

SPONTAN® (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction

About Erectile Dysfunction

Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.

Our Solution

SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects

Commercialisation

LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years

322M

worldwide expected cases by 2025

10

minute effectiveness

$7.10B

projected global market value 2024

Global Market Need

ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.

ON DEMAND
SOLUTION

LTR Pharma Couple

RAPID ONSET
ACTION

BRING BACK
SPONTANEITY

Over 2,000 SPONTAN® units dispensed under Special Access Scheme

LTR Pharma Limited (ASX:LTP) has announced that more than 2,000 bottles of SPONTAN®, our rapid-onset intranasal vardenafil spray, have been dispensed in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme. Highlights: More than 2,000 bottles of SPONTAN® dispensed in Australia under the TGA Special Access Scheme and Authorised

Read More »

First ROXUS® prescriptions fulfilled in the United States

LTR Pharma (ASX: LTP) has confirmed the first patient-specific ROXUS® prescriptions received through Mavrox, Shed’s men’s health telehealth platform, have now been fulfilled in the United States.  ROXUS is LTR Pharma’s intranasal medication for erectile dysfunction support.  The milestone marks the start of prescription activity under LTR Pharma’s agreements with

Read More »

Special Access Scheme

SPONTAN may be prescribed to eligible patients under the TGA’s Special Access Scheme. For more information, please register your details via our online form.

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.